Skip to main content

Research Repository

Advanced Search

All Outputs (52)

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study (2024)
Journal Article
Dupuis, J., Bachy, E., Morschhauser, F., Cartron, G., Fukuhara, N., Daguindau, N., Casasnovas, R.-O., Snauwaert, S., Gressin, R., Fox, C. P., d'Amore, F. A., Staber, P. B., Tournilhac, O., Bouabdallah, K., Thieblemont, C., André, M., Rai, S., Ennishi, D., Gkasiamis, A., Nishio, M., …Lemonnier, F. (2024). Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematology, 11(6), e406-e414. https://doi.org/10.1016/S2352-3026%2824%2900102-9

Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed... Read More about Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2024)
Journal Article
Ferreri, A., Illerhaus, G., Doorduijn, J., Auer, D., Bromberg, J., Calimeri, T., Cwynarski, K., Fox, C., Hoang-Xuan, K., Malaise, D., Ponzoni, M., Schorb, E., Soussain, C., Specht, L., Zucca, E., Buske, C., Jerkeman, M., & Dreyling, M. (2024). Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 35(6), 491-507. https://doi.org/10.1016/j.annonc.2023.11.010

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2024)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Riley, R. D., Warren, R. B., & Williams, H. C. (2024). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, 190(4), 559-564. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases (2024)
Journal Article
Fuller, A., Hancox, J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Maxwell, J. R., Bingham, S., Vedhara, K., & Abhishek, A. (in press). Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases. Rheumatology, Article keae175. https://doi.org/10.1093/rheumatology/keae175

Objective
To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s).

Methods
Adu... Read More about Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases.

Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial (2024)
Journal Article
Howard, R., Cort, E., Rawlinson, C., Wiegand, M., Downey, A., Lawrence, V., …Gould, R. (2024). Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 20(4), 2990-2999. https://doi.org/10.1002/alz.13766

INTRODUCTION: Trials of effectiveness of treatment options for depression in dementia are an important priority. METHODS: Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in mild/moderate dementia caused... Read More about Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article
Abhishek, A., Grainge, M., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., …Riley, R. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10(1), Article e003980. https://doi.org/10.1136/rmdopen-2023-003980

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK (2024)
Journal Article
Bielack, S., Fox, C. P., Hoang‐Xuan, K., Giró‐Perafita, A., & Rizzari, C. (2024). A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK. Health Science Reports, 7(1), Article e1749. https://doi.org/10.1002/hsr2.1749

Introduction: High‐dose methotrexate (HDMTX) is administered for the treatment of some malignancies. Serious complications after the administration of HDMTX are rare, but occasionally MTX may precipitate in the renal tubes causing a delayed eliminati... Read More about A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Preprint / Working Paper
Abhishek, A., Grainge, M. J., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Stevenson, M. D., Nakafero, G., & Riley, R. D. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Richter's transformation: Transforming the clinical landscape (2023)
Journal Article
Barrett, A., Appleby, N., Dreau, H., Fox, C., Munir, T., & Eyre, T. (2024). Richter's transformation: Transforming the clinical landscape. Blood Reviews, 64, Article 101163. https://doi.org/10.1016/j.blre.2023.101163

Richter transformation (RT) represents an aggressive histological transformation from chronic lymphocytic leukaemia, most often to a large B cell lymphoma. It is characterised by chemo-resistance and subsequent short survival. Drug development has st... Read More about Richter's transformation: Transforming the clinical landscape.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/nejmoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis (2023)
Journal Article
Poynton, E., Chernucha, E., Day, J. W., Prodger, C., Hopkins, D., Rakesh, P., O'Neill, T., Thakrar, N., Akarca, A., Jamal, E., Ali, A. S., Kirkwood, A. A., Pomplun, S., Marafioti, T., Calaminici, M., Kirkwood, A. A., Greaves, P., Chaganti, S., McKay, P., Smith, J., …Okosun, J. (2024). Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis. Blood Advances, 8(7), 1772–1775. https://doi.org/10.1182/bloodadvances.2023011426

Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse (2023)
Journal Article
Wilson, M. R., Kirkwood, A. A., Wong Doo, N., Soussain, C., Choquet, S., Lees, C., Fox, C., Preston, G., Ahearne, M., Strüßmann, T., Clavert, A., Rusconi, C., Ku, M., Khwaja, J., Narkhede, M., Lewis, K., Durot, E., Smith, J., Renaud, L., Ferreri, A. J. M., …Eyre, T. A. (2024). Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse. American Journal of Hematology, 99(2), E46-E50. https://doi.org/10.1002/ajh.27167

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., Fox, C. P., Bishton, M., Pender, A., Gleeson, M., Cunningham, D., Davies, A. J., Yadollahi, S., Eyre, T. A., Collins, G. P., Djebbari, F., Kassam, S., Garland, P., Watts, E., Osborne, W., …Linton, K. M. (2024). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, 8(4), 878-888. https://doi.org/10.1182/bloodadvances.2023011305

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma (2023)
Journal Article
Di Ciaccio, P. R., Polizzotto, M. N., Cwynarski, K., Gerrie, A. S., Burton, C., Bower, M., …Hamad, N. (2024). The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood, 143(2), 152-165. https://doi.org/10.1182/blood.2023021348

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavourable prognosis. We conducted a multicenter, international, retrospective cohor... Read More about The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 41(35), 5376-5387. https://doi.org/10.1200/JCO.23.00365

PURPOSE
CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation (2023)
Journal Article
Nakafero, G., Card, T., Grainge, M. J., Williams, H. C., Taal, M. W., Aithal, G. P., …Abhishek, A. (2023). Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. eClinicalMedicine, 64, Article 102213. https://doi.org/10.1016/j.eclinm.2023.102213

Background: Patients established on thiopurines (e.g., azathioprine) are recommended to undergo three-monthly blood tests for the early detection of blood, liver, or kidney toxicity. These side-effects are uncommon during long-term treatment. We deve... Read More about Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation.

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy (2023)
Journal Article
Cornell, I., Al Busaidi, A., Wastling, S., Anjari, M., Cwynarski, K., Fox, C. P., Martinez-Calle, N., Poynton, E., Maynard, J., & Thust, S. C. (2023). Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy. Journal of Personalized Medicine, 13(7), Article 1182. https://doi.org/10.3390/jpm13071182

Primary Central Nervous System Lymphoma (PCNSL) is a highly malignant brain tumour. We investigated dynamic changes in tumour volume and apparent diffusion coefficient (ADC) measurements for predicting outcome following treatment with MATRix chemothe... Read More about Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK (2023)
Journal Article
Nakafero, G., Grainge, M. J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., …Abhishek, A. (2023). Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. BMJ, 381, Article e074678. https://doi.org/10.1136/bmj-2022-074678

OBJECTIVE: To develop and validate a prognostic model to inform risk stratified decisions on frequency of monitoring blood tests during long term methotrexate treatment. DESIGN: Retrospective cohort study. SETTING: Electronic health records within th... Read More about Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.